

## Brineura® (cerliponase alfa) Medication Precertification Request

Page 1 of 1

(All fields must be completed and legible for precertification review.)

Aetna Precertification Notification

Phone: 1-866-752-7021 FAX: 1-888-267-3277

For Medicare Advantage Part B: Please Use Medicare Request Form

Please indicate: Start of treatment: Start date / / / Continuation of therapy: Date of last treatment / / /						
Precertification Requested B		Phone:			Fax:	
A. PATIENT INFORMATION						
First Name:		Last Name:				
Address:		City:			State:	ZIP:
Home Phone:	Work	Phone:		Cell Phone		1
DOB:	Allergies:	E-mail:				
					L-IIIaII.	
Current Weight: lbs	= = = = = = = = = = = = = = = = = = = =	Height:	inches or	cms		
B. INSURANCE INFORMATION						
Aetna Member ID #:		Does patient have other coverage?				
Group #:		If yes, provide ID#: Carrier Name:				
Insured:		nsured:				
Medicare: ☐ Yes ☐ No If yes, provide ID #: Medicaid: ☐ Yes ☐ No If yes, provide ID #:						
C. PRESCRIBER INFORMATION						
First Name:	ITION	Loot Namo:		(Chook O	20): [] M.D. []	D.O.
		Last Name:		-		
Address:	<del></del>	City:			State:	ZIP:
Phone:	Fax:	St Lic #:	NPI #:	DEA #:	l l	JPIN:
Provider E-mail:		Office Contact Name:			Phone:	
Specialty (Check one):						
D. DISPENSING PROVIDER/ADMINISTRATION INFORMATION						
☐ Outpatient Infusion Center Center Name: ☐ Home Infusion Center	Phone:		Dispensing Provider/Pharmacy: (Patient selected choice)  Physician's Office Retail Pharmacy  Specialty Pharmacy Other:  Name:  Address:			
Agency Name	PT\·			Fax:		
Address:	· · //·		TIN:		PIN:	
E. OUTPATIENT INFUSION TREATMENT						
Requesting Outpatient Infusion Treatment?  Yes No If Yes, CPT Code: S9357 96305 96366 Other						
F. PRODUCT INFORMATION						
Request is for: Brineura (cerliponase alfa) Dose: Frequency:						
G. DIAGNOSIS INFORMATION – Please indicate primary ICD code and specify any other where applicable.						
Primary ICD Code: Secondary ICD Code: Other ICD Code:						
H. CLINICAL INFORMATION – Required clinical information must be completed in its entirety for all precertification requests.						
For All Requests (clinical documentation required for all requests):  Yes No Is the patient diagnosed with late infantile neuronal ceroid lipofuscinosis type 2 (CLN2) (also known as tripeptidyl peptidase 1 (TPP1)						
deficiency)?  Yes No Does the patient have intraventricular access device-related complications (e.g., device failure, device-related infection or leakage)						
or ventriculoperitoneal shunts? For Initiation Requests (clinical documentation required for all requests):						
Yes ☐ No Was the diagnosis confirmed by either an enzyme assay demonstrating a deficiency of tripeptidyl peptidase 1 (TPP1) enzyme activity OR by genetic testing?						
☐ Yes ☐ No Will the requested medication be administered by, or under the direction of a physician knowledgeable in intraventricular administration?						
For Continuation Requests (clinical documentation required for all requests):						
Yes No Has the patient experienced no loss of ambulation or a slowed loss of ambulation from baseline?						
Please indicate ambulation status: ☐ No loss of ambulation ☐ Slowed loss of ambulation						
H. ACKNOWLEDGEMENT			,			
Request Completed By (S	Signature Required):				Date:	1 1
Any person who knowingly files a request for authorization of coverage of a medical procedure or service with the intent to injure, defraud or						

a fraudulent insurance act, which is a crime and subjects such person to criminal and civil penalties.